GI Cancers | Clinical

November 24, 2021

Expert perspectives on the case of a 70-year-old man who presents and is diagnosed with solitary hepatocellular carcinoma measuring greater than 3cm.

November 21, 2021

In an interview with Targeted Oncology, Susan Pandya, MD discussed the impact ivosidenib has had on the cholangiocarcinoma space, along with remaining unmet clinical needs.

November 18, 2021

Lynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.

November 17, 2021

In an interview with Targeted Oncology, Katherine Poruk, MD, surgical oncologist, Cancer Treatment Centers of America, discussed the pancreatic treatment paradigm with an emphasis on the role of surgery.

November 15, 2021

Concluding his reflection on novel therapies in patients with cholangiocarcinoma, Milind Javle, MD, provides closing thoughts and practical advice for his community colleagues.

November 15, 2021

Dr Milind Javle discusses novel therapies recently approved or under investigation across multiple lines of therapy in patients with cholangiocarcinoma.

November 15, 2021

Milind Javle, MD, shares his personal experience and insights on the approval and use of infigratinib, an FGFR2 fusion–targeted therapy, in patients with previously treated advanced cholangiocarcinoma.

November 15, 2021

Oncologist Dr. Milind Javel provides an overview of first- and subsequent-line treatments for patients with cholangiocarcinoma.

November 15, 2021

Dr Milind Javle discusses challenges that exist in the early identification of cholangiocarcinoma, as well as the benefits of comprehensive molecular profiling.

November 15, 2021

Expert oncologist Milind Javle, MD, reviews the diagnosis and treatment of intrahepatic cholangiocarcinoma in a 61-year-old who presents with jaundice and changes in stool and urine color.